Revvity upgraded by UBS with a new price target
$RVTY
Biotechnology: Laboratory Analytical Instruments
Industrials
UBS upgraded Revvity from Neutral to Buy and set a new price target of $115.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/1/2025 | $115.00 | Neutral → Buy | UBS |
| 1/10/2025 | $130.00 | Outperform → Mkt Perform | Bernstein |
| 12/13/2024 | $138.00 | Neutral → Buy | BofA Securities |
| 10/15/2024 | $125.00 → $140.00 | Equal Weight → Overweight | Barclays |
| 8/28/2024 | $130.00 | Equal Weight | Wells Fargo |
| 7/8/2024 | $125.00 | Outperform | Leerink Partners |
| 6/3/2024 | $115.00 | Hold | Jefferies |
| 1/16/2024 | $105.00 → $125.00 | Buy → Neutral | UBS |
11-K - REVVITY, INC. (0000031791) (Filer)
SD - REVVITY, INC. (0000031791) (Filer)
10-Q - REVVITY, INC. (0000031791) (Filer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 7, 2025 to all shareholders of record at the close of business on October 17, 2025. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screenin
Revvity, Inc. (NYSE:RVTY), today announced that it will release its second quarter 2025 financial results prior to market open on Monday, July 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflo
Revenue of $665 million; 2% reported growth; 4% organic growth GAAP EPS of $0.35; Adjusted EPS from continuing operations of $1.01 Reaffirms full year 2025 organic growth and adjusted EPS guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as compared to $0.21 in the same period a year ago. Revenue for the quarter was $665 million, as compared to $650 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $72 million, as compared to $44 million for the same period a year ago. GAAP operating profit margin from continu
The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 7, 2025 to all shareholders of record at the close of business on October 17, 2025. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screenin
Revvity, Inc. (NYSE:RVTY), today announced that it will release its second quarter 2025 financial results prior to market open on Monday, July 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflo
Revvity launches its first set of IVD Mimix reference standards, providing diagnostic labs with trusted quality controls for optimizing tests and monitoring workflows Revvity, Inc. (NYSE:RVTY), today announced the launch of three Mimix™ reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) or droplet digital polymerase chain reacting (ddPCR) assays designed to detect somatic mutations in genomic DNA (gDNA) from human samples for IVD use. These cell line-derived reference standards have undergone appropriate design controls to meet U.S. Food and Drug Administration (FDA) regulatory requirements, which helps laboratories integrate them into existing wo
UBS upgraded Revvity from Neutral to Buy and set a new price target of $115.00
Bernstein downgraded Revvity from Outperform to Mkt Perform and set a new price target of $130.00
BofA Securities upgraded Revvity from Neutral to Buy and set a new price target of $138.00
SC 13G/A - REVVITY, INC. (0000031791) (Subject)
SC 13G/A - REVVITY, INC. (0000031791) (Subject)
SC 13G - REVVITY, INC. (0000031791) (Subject)